Liver involvement in patients with systemic lupus erythematosus

Liver involvement in systemic lupus erythematosus is common and in most cases clinical course is asymptomatic, that makes diagnosis difficult. Determination of the cause of the liver involvement is important to select treatment and to evaluate the prognosis of the disease.
The aim of the research was to characterize the clinical features of liver involvement in patients with systemic lupus erythematosus and identify the most significant clinical and laboratory parameters for the differential diagnosis of lupus hepatitis.
Materials and methods. The study included 313 patients with systemic lupus erythematosus observed in the E.M. Tareev Clinic of Rheumatology, Internal Medicine and Occupational Diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University) in the period from 2001 to 2019. The verification of diagnosis of systemic lupus erythematosus was based on the criteria of the American College of Rheumatology (1997). Patients examination included complete blood count, biochemical and immunological blood tests and an abdominal ultrasonography. In 13 cases hepatic autoantibodies (ASMA, anti-LKM-1, LC-1, SLA-LP, AMA-M2) were analyzed, in 4 – magnetic resonance cholangiopancreatography and in 6 – liver biopsy were made.
Results. Liver involvement were represented by an increase of liver enzymes in 58 (18.5%) cases. Chronic viral hepatitis C was diagnosed in 4 (1.3%) patients. Drug-induced hepatitis was found in 17 (5.4%) patients. Autoimmune liver diseases occured in 2 (0.6%) patients. In 2 (0.6%) patients, liver damage was associated with thrombotic microangiopathy (atypical hemolytic uremic syndrome, hereditary thrombophilia). In 15 (4.8%) cases, the most likely diagnosis was NAFLD. Lupus hepatitis was the most likely cause in 18 (5.7%) patients. Differential diagnosis in cases of liver involvement in patients with systemic lupus erythematosus requires assessment of risk factors for various liver diseases, age of the patients, level of liver enzymes, lupus activity, ultrasound signs of liver steatosis and secondary antiphospholipid syndrome.
Determining the cause of the liver involvement for the patients with the systemic lupus erythematosus allows establishing better treatment tactic and improvement of the prognosis.

1. Tareev EM. Collagenoses. Moscow;1965:380 (In Russ.).

2. Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69(2):187-194. doi: 10.1016/0002-9343(80)90378-2

3. Piga M, Vacca A, Porru G, Cauli A, Mathieu A. Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis. Clin Exp Rheumatol. 2010;28(4):504-510.

4. Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol. 2008;35(11):2159-2164. doi: 10.3899/jrheum.080336

5. Bessone F, Poles N, Roma MG. Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. World J Hepatol. 2014;6(6):394-409. doi: 10.4254/wjh.v6.i6.394

6. Brewer BN, Kamen DL. Gastrointestinal and hepatic disease in systemic lupus erythematosus. Rheum Dis Clin North Am. 2018;44(1):165-175. doi: 10.1016/j.rdc.2017.09.011

7. Zheng RH, Wang JH, Wang SB, Chen J, Guan WM, Chen MH. Clinical and immunopathological features of patients with lupus hepatitis. Chin Med J (Engl). 2013;126(2):260-266. doi: 10.3760/cma.j.issn.0366-6999.20121153

8. Khalifa M, Benjazia E, Rezgui A, Ghannouchi N, Alaoua A, Braham A, et al. Lupus hepatitis: A case series of 12 patients. Rev Med Interne. 2011;32(6):347-349. doi: 10.1016/j.revmed.2010.10.357

9. Li C, Zhao J, Zhao Y. Hepatic infarction caused by antiphospholipid syndrome secondary to systemic lupus erythematosus. J Rheumatol. 2019;46(7):755-756. doi: 10.3899/jrheum.181241

10. Maruoka M, Tsunoda S, Furukawa T, Honda O, Yoshikawa T, Fujita K, et al. A case of HELLP syndrome at 34w-pregnancy with systemic lupus erythematosus and antiphospholipid antibody syndrome; Importance of measurement of VW factor. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(2):121-126. doi: 10.2177/jsci.38.121

11. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford). 2007;46(11):1641-1647. doi: 10.1093/rheumatology/kem158

12. Sakhel K, Usta IM, Hannoun A, Arayssi T, Nassar AH. Liver infarction in a woman with systemic lupus erythematosus and secondary anti-phospholipid and HELLP syndrome. Scand J Rheumatol. 2006;35(5):405-408. doi: 10.1080/03009740600588343

13. Efe C, Purnak T, Ozaslan E, Ozbalkan Z, Karaaslan Y, Altiparmak E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus: A retrospective analysis of 147 cases. Scand J Gastroenterol. 2011;46(6):732-737. doi: 10.3109/00365521.2011.558114

14. Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, et al. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: A case report. Ryumachi. 2003;43(4):667-671.

15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928

16. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550-2558. doi: 10.1056/NEJMoa051135

17. Myakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x

18. Hammami S, Chaabane N, Mahmoudi H, Bdioui F, Saffar H. Late-onset systemic lupus erythematosus-associated primary biliary cirrhosis. Int Arch Med. 2013;6(1):3. doi: 10.1186/17557682-6-3

19. Reshetnyak TM, Seredavkina NV, Satybaldyeva MA, Nasonov EL, Reshetnyak VI. Liver transplantation in a patient with primary antiphospholipid syndrome and Budd – Chiari syndrome. World J Hepatol 2015;7(19):2229-2236. doi: 10.4254/wjh.v7.i19.2229

20. Reshetnyak VI, Maev IV, Reshetnyak TM, Zhuravel SV, Pisarev VM. Liver disease and hemostasis (review) Part 2. Cholestatic liver disease and hemostasis. General Reanimatology. 2019;15(6):80-93. doi: 10.15360/1813-9779-2019-6-80-93

21. Reshetniak TM, Ostriakova EV, Patrusheva NL, Patrushev LI, Aleksandrova EN, Seredavkina NV, et al. Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome. Terapevticheskii arkhiv = Therapeutic Archive. 2013;85(1):76-84 (In Russ.).

22. Liu Y, Yu J, Oaks Z, Marchena-Mendez I, Francis L, Bonilla E, et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin Immunol. 2015;160(2):319-327. doi: 10.1016/j.clim.2015.07.001

23. Woods CP, Hazlehurst JM, Tomlinson JW. Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol. 2015;154:94-103. doi: 10.1016/j.jsbmb.2015.07.020

24. Ozaras R, Mert A, Yilmaz MH, Kumbasar H, Tabak F, Ozturk R, et al. Liver involvement in catastrophic antiphospholipid syndrome. Intern Med. 2004;43(4):346-347. doi: 10.2169/internalmedicine.43.346